BridgeBio Pharma Inc
$ 67.68
0.46%
09 Jun - close price
- Market Cap 13,242,180,000 USD
- Current Price $ 67.68
- High / Low $ 69.00 / 65.83
- Stock P/E N/A
- Book Value -11.64
- EPS -3.74
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -17.90 %
- 52 Week High 84.94
- 52 Week Low 38.58
About
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Analyst Target Price
$102.71
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-24 | 2025-10-29 | 2025-08-05 | 2025-04-29 | 2025-02-20 | 2024-11-12 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -0.84 | -0.9389 | -0.72 | -0.95 | -0.9888 | -1.3744 | -0.8596 | -1.01 | -0.12 | -0.96 | -1.08 | -0.96 |
| Estimated EPS | -0.62 | -0.716 | -0.78 | -0.6 | -0.89 | -1.09 | -0.98 | -0.94 | -0.54 | -0.91 | -0.89 | -0.87 |
| Surprise | -0.22 | -0.2229 | 0.06 | -0.35 | -0.0988 | -0.2844 | 0.1204 | -0.07 | 0.42 | -0.05 | -0.19 | -0.09 |
| Surprise Percentage | -35.4839% | -31.1313% | 7.6923% | -58.3333% | -11.1011% | -26.0917% | 12.2857% | -7.4468% | 77.7778% | -5.4945% | -21.3483% | -10.3448% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.58 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BBIO
2026-06-09 07:40:54
An insider at BridgeBio Pharma, Inc. has sold shares valued at $5,413,289, according to a recent SEC filing. The article highlights this transaction and provides an overview of BridgeBio Pharma's stock performance and company profile. It also mentions recent analyst ratings and other company news.
2026-06-08 22:39:42
An officer at BridgeBio Pharma (BBIO.US) recently sold 200,000 shares of common stock for a total of $5.41 million. The transactions occurred between May 27 and June 5, 2026, at prices ranging from $26.985 to $27.10 per share. Following these sales, the officer still holds 1,859,000 shares in the company indirectly.
2026-06-08 21:39:42
BridgeBio Pharma CEO Neil Kumar sold approximately $5.41 million worth of company stock on June 4 and June 5, 2026, through trusts under a Rule 10b5-1 sales plan. Despite the stock's 74% return over the past year, InvestingPro analysis indicates it is slightly overvalued. The company has several drug pipeline developments, including NDA submissions for encaleret and BBP-418, and promising Phase 3 results for acoramidis.
2026-06-08 21:39:42
Family trusts associated with BridgeBio Pharma (BBIO) CEO Neil Kumar sold 80,000 shares of common stock on June 4 and 5, 2026, through a pre-arranged Rule 10b5-1 sales plan. The sales occurred at prices ranging from approximately $65 to $69 per share, totaling over $5.4 million. Despite these sales, Kumar retains significant direct and indirect holdings in the company.
2026-06-08 10:38:53
BridgeBio Pharma (BBIO) is under scrutiny after the FDA granted Priority Review for its BBP-418 New Drug Application, setting a PDUFA action date of November 27, 2026. Despite a strong three-year stock performance, the stock is down year-to-date and trades below some valuation estimates. Analysts suggest a fair value of $102.71 per share, citing growth in rare diseases, profitability, and pipeline potential, although some market indicators like the P/S ratio suggest the market is already pricing in growth and risks.
2026-06-07 23:39:42
This article provides financial data specifically focusing on the "Return on assets %" for BridgeBio Pharma, Inc. (XETR:2CL). It presents a data table showing the period, value, and change in return on assets percentages. The information is sourced from ICE Data Services and FactSet Research Systems Inc.
